^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Plasma-SeqSensei™ CRC Kit

    Company:
    Sysmex Corp
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    7ms
    Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies. (PubMed, J Anus Rectum Colon)
    A total of 240 patients will be accrued over 2 years. These trials will help us understanding the clinical significance of spatial and temporal heterogeneities of RAS, BRAF and other genes, while optimizing the anti-EGFR mAb treatment strategies in mCRC.
    Journal • Circulating tumor DNA • Metastases
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RAS (Rat Sarcoma Virus)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    Plasma-SeqSensei™ CRC Kit
    over1year
    The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy (ESMO 2023)
    Conclusions Our prospective observational study revealed the efficacy of anti-EGFR therapy for RAS mutant mCRC pts with RAS mts negative in ctDNA after 1st- or 2nd-line treatment. Further prospective studies need to be conducted for these pts.
    Clinical • Circulating tumor DNA • Metastases
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    RAS mutation • RAS wild-type
    |
    OncoBEAM RAS CRC kit • Plasma-SeqSensei™ CRC Kit